Clinical Trial Update: Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects [Phase 1]

View source ↗

Summary

A Phase 1 safety study of intravenous 6β-naltrexol (AIKO-150) in individuals with opioid use disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• 6β-Naltrexol (AIKO-150) intravenous (6β-Naltrexol)

Snippet

Sponsor: California Pacific Medical Center Research Institute | Conditions: Opiate Addiction | Phase 1 | Status: COMPLETED